Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Jinan 250021, PR China.
Neuro Oncol. 2010 Aug;12(8):799-803. doi: 10.1093/neuonc/noq024. Epub 2010 Mar 3.
Hepatocyte growth factor (HGF) and its receptor c-Met have been known as key determinants of growth and angiogenesis in some brain tumors like gliomas, meningiomas, and schwannomas. But little is known about their expression in pituitary adenomas. In this study, the expression of HGF and c-Met in pituitary adenomas of different histology types was investigated by immunohistochemistry, and correlative analysis of their expression with microvessel density (MVD), Ki-67 expression, and other clinicopathologic factors was made. The results showed that the expression of HGF and c-Met exists in 98% (64 of 65) and 92% (60 of 65) pituitary adenomas, respectively, and co-expression of them existed in 91% (59 of 65) adenomas. HGF had significant correlation with MVD (Spearman's correlation coefficient, r = .31, P = .01) and Ki-67 (r = .32, P = .01). c-Met had significant correlation with MVD (r = .30, P = .02) and Ki-67 (r = .38, P = .00). HGF and c-Met expression had no significant correlation with age or extrasellar extension. There were no significant differences in HGF and c-Met expression between pituitary adenomas of different histology types. The results indicate that HGF and c-Met are widely expressed in pituitary adenomas, and their expression correlates with MVD and Ki-67 expression.
肝细胞生长因子 (HGF)及其受体 c-Met 已被认为是某些脑肿瘤(如神经胶质瘤、脑膜瘤和神经鞘瘤)生长和血管生成的关键决定因素。但是,关于它们在垂体腺瘤中的表达知之甚少。在这项研究中,通过免疫组织化学研究了不同组织学类型的垂体腺瘤中 HGF 和 c-Met 的表达,并对其表达与微血管密度(MVD)、Ki-67 表达和其他临床病理因素进行了相关性分析。结果表明,HGF 和 c-Met 的表达存在于 98%(64/65)和 92%(60/65)的垂体腺瘤中,分别存在于 91%(59/65)的腺瘤中。HGF 与 MVD(Spearman 相关系数,r =.31,P =.01)和 Ki-67(r =.32,P =.01)有显著相关性。c-Met 与 MVD(r =.30,P =.02)和 Ki-67(r =.38,P =.00)有显著相关性。HGF 和 c-Met 的表达与年龄或鞍外扩展无关。不同组织学类型的垂体腺瘤中 HGF 和 c-Met 的表达无显著差异。结果表明,HGF 和 c-Met 在垂体腺瘤中广泛表达,其表达与 MVD 和 Ki-67 表达相关。